Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / RPSA



This biomarker is also known as:
  • ribosomal protein SA,
  • p40,
  • Laminin-binding protein precursor p40,
  • LAMBR,
  • LAMR1,
  • NEM/1CHD4,
  • 40S ribosomal protein SA,
  • LRP/LR,
  • RSSA,
  • LamR,
  • Colon carcinoma laminin-binding protein,
  • 34/67 kDa laminin receptor,
  • 67kD, ribosomal protein SA,
  • laminin receptor 1,
  • Multidrug resistance-associated protein MGr1-Ag,
  • laminin receptor 1 (67kD, ribosomal protein SA),
  • LRP,
  • 37LRP,
  • LBP/p40,
  • 67LR,
  • LBP,

View in BioMuta


Laminins, a family of extracellular matrix glycoproteins, are the major noncollagenous constituent of basement membranes. They have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth and metastasis. Many of the effects of laminin are mediated through interactions with cell surface receptors. These receptors include members of the integrin family, as well as non-integrin laminin-binding proteins. The amino acid sequence of laminin receptor 1 is highly through evolution, suggesting a key biological function. It has been observed that the level of the laminin receptor transcript is higher in colon carcinoma tissue and lung cancer cell line than their normal counterparts. Also, there is a correlation between the upregulation of this polypeptide in cancer cells and their invasive and metastatic phenotype. Cell-adhesive protein LAMR1 plays an important role in the processes of cancer proliferation, invasion and metastasis. LAMR1 antigens have been found to be targets of autoantibodies in subjects newly diagnosed with lung cancer.


QA State: Accepted
Type: Protein
Short Name:


The following organs have data associated with this biomarker…



Phase: Three
QA State: Under Review


LAMR1, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including LAMR1.

Performance Comment

The findings of this study suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens. Investigation of LAMR1 (RPSA) is ongoing.

Supporting Study Data

The following studies/protocols provide evidence supporting RPSA indications for the Lung…

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. 51.0 82.0 N/A N/A N/A
Decision Rule


Additional Study-Specific Protocols
Study-Specific Publications
Study-Specific Resources

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.